My Journey

and 2 cents worth...

Patient Resources Transportation, Housing, Drug Discount Programs, Social Security-Disability Links

Research your options!

Clinical Trials

Melanoma News 

Latest Results from Clinical Trials

A Few  Melanoma Treatment Centers  

that conduct NIH approved clinical trials     (click on the centers name )

Social Networks & Helpful Websites

I'm a Stage IV

Melanoma Survivor!

June 18, 2009 I was diagnosed with Stage IV Melanoma  and given the standard 6-9 months before my clock ran out...

April 5, 2013 I finished my last infusion of Nivolumab (Bristol Meyers Squibb's Anti PD-1) in a 30 month clinical trial with Dr.Weber at Moffitt Cancer Center in Tampa, Florida.

I have had NO  evidence of disease. As of today 6/13/2014- it's been over  4  years  (March 26, 2014) that and I remain NED.                                                     ...My life  was interrupted but I'm still standing! 

Inside look at my Melanoma Center~ H. Lee Moffitt- Tampa, Florida

As you  can see, I am fond of Moffitt!  I highly recommend Moffitt from personal experience.  I have high praise for the cutaneous clinic, the clinical research unit and their AWESOME oncologists! Moffitt Cancer Center is one of 41 NCI-designated comprehensive cancer centers in the country and the only one in Florida. Below I have listed the current clinical trials currenly open at Moffitt.

Click HERE to  find more information about a specific trial!

The mission of Moffitt Cancer Center

is to contribute

to the prevention and cure of cancer.

Melanoma / Skin Cancer news headlines provided courtesy of Medical News Today.

A day at Disney World with my Hubby and my floppy hat to protect me from the Florida UV rays!   Summer 2012.

My Hubby and I at Mayo Clinic just before my biopsy June 2009.

Melanoma News-By Lynn  (Click) My Facebook group where  I post News and updates . I have many PDF and Word doc files uploaded.

Anti PD-1  ACCESS!!!! Available NOW!!


Clinical Trails currently at Moffitt  for Skin/ Melanoma

Updated from Moffitt website on March 14, 2014

If you believe you are eligible for one of these trials or studies, please call 1-888-MOFFITT (1-888-663-3488) and select option #2.   CLINICAL TRIAL 14120 Multicenter Selective Lymphadenectomy Trial II (MSLT-II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node 
CLINICAL TRIAL 14715 Master Protocol That Serves as a Companion Protocol for ECOG and CTSU Companion Protocol for E2603

CLINICAL TRIAL 15400 A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of anti-PD-1 Antibody BMS-936558 for Patients with Unresectable Stages III/IV Melanoma 

​ CLINICAL TRIAL 15651 A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of Anti-PD-1 Antibody BMS-936558 or Ipilimumab with BMS-936558 for Patients with Resected Stages IIIC/IV Melanoma 

CLINICAL TRIAL 15677 Collection of Blood Mononuclear Cells by Aphresis From Compensated Volunteer Healthy Donors 

​ CLINICAL TRIAL 16545 A Randomized Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI with or without Poly IC:LC in Patients with Resected MAGE-A3 Positive, Stage IV Melanoma 

CLINICAL TRIAL 16733 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

CLINICAL TRIAL 16959 A Study to Detect Upregulation of Mannose Phosphate Receptor (MPR) Expression and Autophagy in Subjects with Unresectable Stage III or Stage IV Melanoma Who Received a B-RAF Inhibitor or a Taxol-Containing Chemotherapy Regimen 

CLINICAL TRIAL 16977 Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients with Melanoma 

CLINICAL TRIAL 16992 A Phase II Clinical Trial of Vemurafenib with Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients with Metastatic Melanoma 

​ CLINICAL TRIAL 16998 An Open-label, Multicenter, Phase II Study of Continuous Oral Vemurafenib in Patients with Locally Advanced, Unresectable, Stage IIIC or Metastatic Melanoma and Activating Exon 15 BRAF Mutations other than V600E

CLINICAL TRIAL 17013 Phase I Study of Escalating Doses of XL888 with Vemurafenib for Patients with Unresectable BRAF Mutated Stage III/IV Melanoma 

CLINICAL TRIAL 17017 A Phase 1A/1B, Multicenter, Open Label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and or Kinase Inhibitor, CC-115, Administered Orally to Subjects with Advanced Solid Tumors and Hematologic Malignancies 

CLINICAL TRIAL 17019 A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination with INCB024360 or Placebo in Subjects with Unresectable or Metastatic Melanoma 

CLINICAL TRIAL 17057 A Pilot Feasibility Trial of Ipilimumab with Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients with Metastatic Melanoma

CLINICAL TRIAL 17099 Proleukin® Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

​ CLINICAL TRIAL 17148 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors 

CLINICAL TRIAL 17183 Detection of immune cell infiltration into melanomas treated by PV-10, a feasibility study 

CLINICAL TRIAL 17218 A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients 

CLINICAL TRIAL 17243 A Phase 2 Study of Ipilimumab in Children and Adolescents 12 to < 18 years with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma 

CLINICAL TRIAL 17261 A Phase I Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered with Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects with Select Advanced Solid Tumors 

CLINICAL TRIAL 17365 An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially with Ipilimumab in Subjects with Advanced or Metastatic Melanoma 

​ CLINICAL TRIAL 17377 COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation with (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-Risk BRAF V600 Mutation-Positive Melanoma After Surgical Resection 

CLINICAL TRIAL 17393 A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer 

CLINICAL TRIAL 17439 A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination with Ipilimumab in Subjects with Unresectable Stage III or Stage IV Melanoma 

​ CLINICAL TRIAL 17622 Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein with GLA-SE Adjuvant in Patients with Unresectable or Metastatic Cancer Expressing NY-ESO-1 Antigen